Novolog (Pharm-Up 1966) Ltd (NVLG.TA)
- Previous Close
142.00 - Open
143.00 - Bid 137.40 x --
- Ask 137.50 x --
- Day's Range
137.40 - 144.20 - 52 Week Range
135.00 - 196.00 - Volume
1,030,864 - Avg. Volume
264,146 - Market Cap (intraday)
701.897M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
17.17 - EPS (TTM)
0.08 - Earnings Date --
- Forward Dividend & Yield 0.08 (5.52%)
- Ex-Dividend Date Dec 2, 2024
- 1y Target Est
--
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Health Services, and Digital. The Logistics division engages in the import and distribution of medicine and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation processes of consumable medical equipment. The Health Services division provides customized medicine, medical and diagnostic laboratory, and other medical services to patients, health organizations, insurance companies, multinational companies, and government bodies. The Digital division develops technological tools for health services; deals with making medical information accessible to the public through medical websites; promotes digital presence for clinics, doctors therapists, and medical bodies; provides services and management tools; and operates and markets digital platforms for doctors and clinics. Novolog (Pharm-Up 1966) Ltd was incorporated in 1966 and is headquartered in Modi'in-Maccabim-Re'ut, Israel.
www.novolog.co.il936
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVLG.TA
View MorePerformance Overview: NVLG.TA
Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVLG.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVLG.TA
View MoreValuation Measures
Market Cap
701.90M
Enterprise Value
652.77M
Trailing P/E
17.84
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
1.91
Enterprise Value/Revenue
0.32
Enterprise Value/EBITDA
4.37
Financial Highlights
Profitability and Income Statement
Profit Margin
1.96%
Return on Assets (ttm)
1.56%
Return on Equity (ttm)
10.53%
Revenue (ttm)
2.02B
Net Income Avi to Common (ttm)
39.54M
Diluted EPS (ttm)
0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
247.6M
Total Debt/Equity (mrq)
51.94%
Levered Free Cash Flow (ttm)
89M